The Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL.
In the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (2010–2013), central Iran. Immunohistochemical method was used for detecting biomarkers such as CD2, CD3, CD20 and CD45.
In this study, 54.5% of the patients were men and 45.5% were women. Most of the patients were 40-50 years old. Moreover, 10 (22.7%) patients had lymph node metastasis and 6 (13.6%) patients had stomach involvement. Positive expression of CD45 and CD20 biomarkers were expressed in 100% and 97.7% of the patients. Positive expression of CD3 and CD2 was expressed in 40.9% and 81.8% of the patients, respectively. C-expression of CD45 and CD20 biomarkers was seen in 43 patients. Moreover, there was no relation between biomarkers and sex and age (P>0.05).
The result of this study showed that high number of CD45 and CD20 have been seen in Iran’s population. Moreover expression of CD20 and CD45 is different as compared with other populations. It seems that these differences can be due to ethnic groups and nature of malignant cells.